Overview

IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis

Status:
Completed
Trial end date:
2019-07-24
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety and efficacy of intravenous (iv) or iv/per oral (po) omadacycline as compared to iv or iv/po levofloxacin in the treatment of female adults with acute pyelonephritis.
Phase:
Phase 2
Details
Lead Sponsor:
Paratek Pharmaceuticals Inc
Treatments:
Levofloxacin
Ofloxacin